IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
HONG KONG
NOVARTIS
Full Name: Novartis Pharmaceuticals (HK) Ltd
Street Ad dress: Room 3703-4 Wind sor House,
311 Glou ces ter Rd, Cause way Bay
Tel: +852 2882 5222
Fax: +852 2577 8003
Email: info.hk@pharma.novartis.com
Home Page: www.hk.novartis.com
De scrip tion: De vel oper, pro moter,
sales/detailer. Prod uct ranges in clude: phar ma -
ceu ti cal prod ucts (branded, pre scrip tion,
non-pre scrip tion), bio tech nol ogy prod ucts, di -
etetic/nu tri tional prod ucts, oph thal mic prod ucts,
vet er i nary pharmaceuticals. Es tab lished 1997. 80
phar ma ceu ti cal em ploy ees in 2007. Di vi sions
include: Novartis Consumer Health.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 21-50 (2007)
Con tacts (Pharm): Chair man: James Hsiao;
Gen eral Con tact: James Hsiao
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 28-30 mil lion
Prod ucts (% of Sales by Lead ing 5): 45-50%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
85-90%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
SANDIMMUN NEORAL (immunosuppressive
agent)
DIOVAN (an gio ten sin-II an tag o nist plain)
FEMARA (cytostatic hor mone an tag o nist)
CO-DIOVAN (an gio ten sin-II an tag o nist com bi na -
tion)
Ther a peu tic Range:
antineoplastics 22%
immunosuppressive agents 15%
renin-an gio ten sin sys tem agents 12%
ophthalmologicals 9%
antiepileptics 4%
Lead ing Dose Forms:
cap sules 38%
coated tab lets 27%
tab lets 11%
vi als 7%
in fu sions 6%
HUNGARY
NOVARTIS
Full Name: Novartis Hun gary Healthcare LLC
Postal Ad dress: H-1537 Bu da pest, PO Box
453/80
Street Ad dress: H-1114 Bu da pest, Bartok Haz,
Bartok Bela ut 43-47
Tel: +36 1 457-6500
Fax: +36 1 457-6600
Home Page: www.novartis.hu
De scrip tion: Di vi sions in clude: Novartis Sandoz.
Con tacts (Pharm): Chair man: Altan
Demirdere; Com mer cial Op er a tions: Beata
Bordas
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 160-170 mil lion
Prod ucts (% of Sales by Lead ing 5): 50-55%
Ther a peu tic Classes (% of Sales by Lead ing
5): 55-60%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
DIOVAN HCT (an gio ten sin-II an tag o nist com bi na -
tion)
FEMARA (cytostatic hor mone an tag o nist)
LESCOL (cho les terol/triglyceride reg u lat ing prep -
a ra tion)
ZOMETA (bone cal cium reg u la tor)
Ther a peu tic Range:
antineoplastics 20%
renin-an gio ten sin sys tem agents 15%
cytostatic hor mone ther apy 9%
anti rheu ma tics sys temic 8%
musculoskeletal drugs other 8%
Lead ing Dose Forms:
coated tab lets 64%
tab lets 9%
in fu sions 9%
med i cal dress ings 5%
cap sules 5%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Hun gary Healthcare LLC
Postal Ad dress: H-1525 Bu da pest, PO Box 118
Street Ad dress: H-1114 Bu da pest, Bartok Haz,
Bartok Bela ut 43-47
Tel: +36 1 457-6656
Fax: +36 1 457-6647
Home Page: www.novartis.hu
© 2009 IMS Health In cor po rated or its af fil i ates Page 175